Gilead Sciences (NASDAQ:GILD) Stock: Insider Daniel Patrick O'day Sells 9,810 Shares

November 7, 2026 by InsiderTrades.com

Key Points

Gilead CEO Daniel O’Day sold 102,619 shares for about $18 million on November 4; the sale was made under a pre-arranged Rule 10b5-1 plan. He retained 551,683 shares after the transaction.
Gilead’s latest quarterly results topped analyst expectations, with earnings of $2.55 per share and revenue of $8.30 billion; revenue rose 6.8% year over year.
The company declared a quarterly dividend of $0.82 per share, equivalent to $3.28 annually and a reported 2.0% yield.

Gilead Sciences logo Gilead Sciences, Inc. (NASDAQ:GILD - Get Free Report) CEO Daniel O'Day sold 9,810 shares of the stock in a transaction dated Thursday, November 5th. The shares were sold at an average price of $175.17, for a total value of $1,718,417.70. Following the completion of the transaction, the chief executive officer directly owned 551,683 shares in the company, valued at $96,638,311.11. This represents a 1.75% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

3 Blue-Chip Stocks Built for a Rotating Market

Daniel Patrick O'day also recently made the following trade(s):

On Wednesday, November 4th, Daniel O'Day sold 102,619 shares of Gilead Sciences stock. The shares were sold at an average price of $175.16, for a total transaction of $17,974,744.04.
On Monday, November 2nd, Daniel O'Day sold 15,000 shares of Gilead Sciences stock. The stock was sold at an average price of $169.74, for a total value of $2,546,100.00.
On Friday, October 30th, Daniel O'Day sold 15,881 shares of Gilead Sciences stock. The shares were sold at an average price of $175.25, for a total value of $2,783,145.25.
On Thursday, October 1st, Daniel O'Day sold 15,000 shares of Gilead Sciences stock. The shares were sold at an average price of $147.90, for a total transaction of $2,218,500.00.
On Tuesday, September 1st, Daniel O'Day sold 15,000 shares of Gilead Sciences stock. The shares were sold at an average price of $148.64, for a total value of $2,229,600.00.

Gilead Sciences Stock Down 0.4%

Shares of GILD stock opened at $166.89 on Friday. The company has a quick ratio of 0.95, a current ratio of 1.38 and a debt-to-equity ratio of 1.84. Gilead Sciences, Inc. has a one year low of $116.88 and a one year high of $176.58. The stock has a fifty day moving average price of $153.04 and a 200 day moving average price of $140.94.

These 3 Cash Flow Machines Provide Stability in Uncertain Markets

Gilead Sciences (NASDAQ:GILD - Get Free Report) last posted its quarterly earnings data on Thursday, October 29th. The biopharmaceutical company reported $2.55 earnings per share for the quarter, topping the consensus estimate of $2.19 by $0.36. Gilead Sciences had a negative return on equity of 1.85% and a negative net margin of 12.47%. The company had revenue of $8.30 billion during the quarter, compared to analysts' expectations of $7.81 billion. During the same period in the prior year, the firm earned $2.47 earnings per share. Gilead Sciences's revenue for the quarter was up 6.8% compared to the same quarter last year. Research analysts anticipate that Gilead Sciences, Inc. will post -1.07 EPS for the current fiscal year.

Gilead Sciences Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, December 30th. Shareholders of record on Tuesday, December 15th will be issued a dividend of $0.82 per share. This represents a $3.28 dividend on an annualized basis and a yield of 2.0%. The ex-dividend date of this dividend is Tuesday, December 15th. Gilead Sciences's payout ratio is currently -103.80%.

Institutional Inflows and Outflows

3 Cash-Flow Machines Investors May Want Heading Into 2026

Institutional investors have recently bought and sold shares of the business. BlackRock Inc. acquired a new stake in Gilead Sciences during the second quarter worth approximately $15,393,785,000. State Street Corp raised its position in shares of Gilead Sciences by 2.3% in the second quarter. State Street Corp now owns 61,216,552 shares of the biopharmaceutical company's stock valued at $7,734,099,000 after purchasing an additional 1,357,967 shares during the period. Amundi lifted its stake in Gilead Sciences by 10.7% during the first quarter. Amundi now owns 10,539,111 shares of the biopharmaceutical company's stock worth $1,468,836,000 after purchasing an additional 1,018,976 shares during the period. Legal & General Group Plc acquired a new stake in shares of Gilead Sciences in the second quarter valued at approximately $1,316,606,000. Finally, Deutsche Bank AG acquired a new position in shares of Gilead Sciences in the 2nd quarter valued at $918,387,000. 83.67% of the stock is currently owned by institutional investors and hedge funds.

Key Headlines Impacting Gilead Sciences

Here are the key news stories impacting Gilead Sciences this week:

Positive Sentiment: New HIV-prevention data showed twice-yearly lenacapavir achieved nearly twice the one-year treatment persistence of daily oral F/TDF, a result that could support Gilead’s long-acting HIV-prevention strategy. Article: New Data Show Twice-Yearly Lenacapavir Achieved Nearly Twice the One-Year Persistence
Positive Sentiment: In the Phase 3 IDEAL study, Livdelzi (seladelpar) achieved ALP normalization in about 75% of participants with primary biliary cholangitis. The results may strengthen its case for broader second-line use, although the stock reportedly fell following the update. Article: Gilead's Livdelzi Achieves 75% ALP Normalization
Positive Sentiment: Recent third-quarter results beat analyst estimates for earnings and revenue, and Gilead raised full-year product-sales guidance. The company also maintained its quarterly dividend at $0.82 per share. Article: Did Earnings Beat Just Shift Gilead Sciences' Investment Narrative?
Neutral Sentiment: CEO Daniel O’Day sold more than 112,000 shares across November 4–5, but the transactions were conducted under a pre-arranged Rule 10b5-1 plan. He retained 551,683 shares, which may temper concerns about the sales. SEC Form 4 filing

Analysts Set New Price Targets

GILD has been the topic of a number of recent analyst reports. Truist Financial increased their price objective on Gilead Sciences from $158.00 to $181.00 and gave the stock a "buy" rating in a research report on Friday, October 30th. Morgan Stanley increased their price target on shares of Gilead Sciences from $163.00 to $183.00 and gave the stock an "overweight" rating in a research note on Friday, October 30th. Royal Bank Of Canada boosted their target price on Gilead Sciences from $126.00 to $131.00 and gave the stock a "sector perform" rating in a report on Friday, October 30th. TD Cowen upped their price target on Gilead Sciences from $160.00 to $175.00 and gave the company a "buy" rating in a report on Friday, October 30th. Finally, Bank of America raised their target price on Gilead Sciences from $168.00 to $172.00 and gave the stock a "buy" rating in a research report on Tuesday, October 20th. Twenty-three equities research analysts have rated the stock with a Buy rating and six have given a Hold rating to the company's stock. Based on data from MarketBeat, Gilead Sciences presently has a consensus rating of "Moderate Buy" and a consensus price target of $170.15.

Get Our Latest Stock Analysis on GILD

About Gilead Sciences

(Get Free Report)

Gilead Sciences, Inc is a biopharmaceutical company that discovers, develops and commercializes medicines for serious diseases. Founded in 1987 and headquartered in Foster City, California, the company focuses on antiviral therapies, including treatments and preventive medicines for HIV and medicines for viral hepatitis. Its products include Biktarvy for HIV and Epclusa for hepatitis C.

Gilead also develops medicines in areas such as oncology and inflammatory diseases. Its portfolio includes Veklury (remdesivir), an antiviral medicine used to treat COVID-19.